294 related articles for article (PubMed ID: 21073718)
1. A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.
Khetawat D; Broder CC
Virol J; 2010 Nov; 7():312. PubMed ID: 21073718
[TBL] [Abstract][Full Text] [Related]
2. Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.
Bradel-Tretheway BG; Zamora JLR; Stone JA; Liu Q; Li J; Aguilar HC
J Virol; 2019 Jul; 93(13):. PubMed ID: 30971473
[TBL] [Abstract][Full Text] [Related]
3. Headless Henipaviral Receptor Binding Glycoproteins Reveal Fusion Modulation by the Head/Stalk Interface and Post-receptor Binding Contributions of the Head Domain.
Yeo YY; Buchholz DW; Gamble A; Jager M; Aguilar HC
J Virol; 2021 Sep; 95(20):e0066621. PubMed ID: 34288734
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage.
Negrete OA; Chu D; Aguilar HC; Lee B
J Virol; 2007 Oct; 81(19):10804-14. PubMed ID: 17652392
[TBL] [Abstract][Full Text] [Related]
5. A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.
Amaya M; Yin R; Yan L; Borisevich V; Adhikari BN; Bennett A; Malagon F; Cer RZ; Bishop-Lilly KA; Dimitrov AS; Cross RW; Geisbert TW; Broder CC
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243163
[TBL] [Abstract][Full Text] [Related]
6. Prefusion stabilization of the Hendra and Langya virus F proteins.
Byrne PO; Blade EG; Fisher BE; Ambrozak DR; Ramamohan AR; Graham BS; Loomis RJ; McLellan JS
J Virol; 2024 Feb; 98(2):e0137223. PubMed ID: 38214525
[TBL] [Abstract][Full Text] [Related]
7. Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade.
Zamora JLR; Ortega V; Johnston GP; Li J; André NM; Monreal IA; Contreras EM; Whittaker GR; Aguilar HC
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669342
[TBL] [Abstract][Full Text] [Related]
8. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.
Yun T; Park A; Hill TE; Pernet O; Beaty SM; Juelich TL; Smith JK; Zhang L; Wang YE; Vigant F; Gao J; Wu P; Lee B; Freiberg AN
J Virol; 2015 Jan; 89(2):1242-53. PubMed ID: 25392218
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided mutagenesis of Henipavirus receptor-binding proteins reveals molecular determinants of receptor usage and antibody-binding epitopes.
Oguntuyo KY; Haas GD; Azarm KD; Stevens CS; Brambilla L; Kowdle SS; Avanzato VA; Pryce R; Freiberg AN; Bowden TA; Lee B
J Virol; 2024 Mar; 98(3):e0183823. PubMed ID: 38426726
[TBL] [Abstract][Full Text] [Related]
10. Henipavirus mediated membrane fusion, virus entry and targeted therapeutics.
Steffen DL; Xu K; Nikolov DB; Broder CC
Viruses; 2012 Feb; 4(2):280-308. PubMed ID: 22470837
[TBL] [Abstract][Full Text] [Related]
11. A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics.
Wolf MC; Wang Y; Freiberg AN; Aguilar HC; Holbrook MR; Lee B
Virol J; 2009 Jul; 6():119. PubMed ID: 19646266
[TBL] [Abstract][Full Text] [Related]
12. Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins.
Bossart KN; Wang LF; Flora MN; Chua KB; Lam SK; Eaton BT; Broder CC
J Virol; 2002 Nov; 76(22):11186-98. PubMed ID: 12388678
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.
Porotto M; Carta P; Deng Y; Kellogg GE; Whitt M; Lu M; Mungall BA; Moscona A
J Virol; 2007 Oct; 81(19):10567-74. PubMed ID: 17652384
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of henipavirus infection by Nipah virus attachment glycoprotein occurs without cell-surface downregulation of ephrin-B2 or ephrin-B3.
Sawatsky B; Grolla A; Kuzenko N; Weingartl H; Czub M
J Gen Virol; 2007 Feb; 88(Pt 2):582-591. PubMed ID: 17251577
[TBL] [Abstract][Full Text] [Related]
15. Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice.
Li Y; Li R; Wang M; Liu Y; Yin Y; Zai X; Song X; Chen Y; Xu J; Chen W
Viruses; 2020 Apr; 12(4):. PubMed ID: 32340278
[TBL] [Abstract][Full Text] [Related]
16. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein.
Kaku Y; Noguchi A; Marsh GA; McEachern JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang LF
J Virol Methods; 2009 Sep; 160(1-2):7-13. PubMed ID: 19433112
[TBL] [Abstract][Full Text] [Related]
17. Cell-Cell Fusion Assays to Study Henipavirus Entry and Evaluate Therapeutics.
Monreal IA; Aguilar HC
Methods Mol Biol; 2023; 2682():59-69. PubMed ID: 37610573
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
[TBL] [Abstract][Full Text] [Related]
19. Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus.
Bradel-Tretheway BG; Liu Q; Stone JA; McInally S; Aguilar HC
J Virol; 2015 Jul; 89(14):7235-47. PubMed ID: 25948743
[TBL] [Abstract][Full Text] [Related]
20. A recombinant Cedar virus based high-throughput screening assay for henipavirus antiviral discovery.
Amaya M; Cheng H; Borisevich V; Navaratnarajah CK; Cattaneo R; Cooper L; Moore TW; Gaisina IN; Geisbert TW; Rong L; Broder CC
Antiviral Res; 2021 Sep; 193():105084. PubMed ID: 34077807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]